Eight firms, 29 peptide products, four Class I recalls
Between July 1 and October 1, 2026, eight compounding firms began recalls of peptide products. All four Class I recalls involve glutathione, three of them over bacterial endotoxin results. We found no qualifying recall begun or classified October 20–27.
This tracker lists FDA recalls of compounded peptide products, newest first. Each entry links to its FDA Enforcement Report record. To check a product you have, find the pharmacy below, open its product list, and compare the lot number and beyond-use date on your label.
Records checked October 27, 2026: the FDA's weekly Enforcement Report of October 21, 2026, daily postings through October 26, 2026, and openFDA data last updated October 21, 2026. Product names, lot numbers, quantities and reasons use the FDA's wording, including its typos.
Greenwich Rx
Glutathione · Tomball, TX · 503A pharmacy
- Recall started
- October 1, 2026
- FDA classified
- Not yet published by FDA
- Public announcement
- October 1, 2026
- Status in FDA record
- Ongoing
FDA reason: “Microbial Contamination of Sterile Products”
FDA's record shows Class I but no classification date, recall number, or quantity yet. The company's announcement reports two patients who received emergency care after IV administration of a product not formulated for IV use.
1 recalled product: lots and dates
Glutathione injection, 200 mg/mL, 10 mL vial
Lots (FDA wording): Lot # 0060-062426-1, BUD: 10/02/2026; Lot # 0060-062726-1, BUD: 10/05/2026; Lot # 0060-070926-1, BUD: 10/17/2026; Lot # 0060-071426-1, BUD: 10/22/2026; Lot #0060-071426-2, BUD: 10/22/2026; Lot # 0060-072026-1, BUD: 10/28/2026; Lot # 0060-072726-1, BUD: 11/04/2026; Lot #0060-072926-1, BUD: 11/06/2026; Lot # 0060-073126-1; BUD: 11/08/2026; Lot # 0060-080426-1, BUD: 11/12/2026; Lot #: 0060-080526-1, BUD: 11/13/2026; Lot # 0060-081826-1, BUD: 11/26/2026.
Quantity (FDA field): N/A
FDA description: Glutathione Injection (Glutathione-L, Ascorbic Acid, Sodium Hydroxide, Bacteriostatic Water), 200 mg/mL, 10 mL multi-dose vial, Rx only, Greenwich Rx.
Recall number: Not yet published by FDA
FDA Enforcement Report, event 100004 · Distribution: US Nationwide in th USA
Houston Rx LLC
Tirzepatide/niacinamide; sermorelin · Houston, TX · 503A pharmacy
- Recall started
- September 25, 2026
- FDA classified
- October 13, 2026
- Public announcement
- None found
- Status in FDA record
- Ongoing
FDA reason: “Lack of assurance of sterility.”
2 recalled products: lots and dates
Tirzepatide/niacinamide, 2 mL vial
Lots (FDA wording): Lot# TZN-080326-20/2-2, Beyond Use Date: 12/01/2026.
Quantity (FDA field): 64 vials
FDA description: Tirzepatide/Niacinamide 2mL vial (40 MG per Vial) Inj 20mg/2mg/mL, RX Only, Houston RX LLC, 15430 Vantage Parkway E STE 220, Houston, TX 77032.
Recall number: D-0040-2027
Sermorelin, 1 mg/mL, 10 mL vial
Lots (FDA wording): Lot# SER-081726-1-10, Beyond Use Date: 10/01/2026.
Quantity (FDA field): 7 vials
Reason for this product: “Lack of process control”
FDA description: Sermorelin, 1 mg/mL, 10 ml vial, Sterile injectable solution, RX Only, Houston RX LLC, 15430 Vantage Parkway E STE 220, Houston, TX 77032.
Recall number: D-0041-2027
FDA Enforcement Report, event 99990 · Distribution: Nationwide in the USA.
Apothecary Pharma LLC
Tirzepatide · Cary, NC · 503B outsourcing facility
- Recall started
- September 24, 2026
- FDA classified
- October 8, 2026
- Public announcement
- None found
- Status in FDA record
- Ongoing
FDA reason: “Lack of Assurance of Sterility”
The same FDA event also recalls 1 vial of NAD+ injection (not a peptide). FDA's quantity is 22 vials; the record separately lists 22 lot identifiers.
1 recalled product: lots and dates
Tirzepatide injection, 18 mg/mL, 4 mL vial
Lots (FDA wording): Lot #: AP-202622, BUD 07-Oct-2026; AP-202623, BUD 08-Oct-2026; AP-202624, BUD 19-Oct-2026; AP-202625, BUD 10/20/2026; AP-202627, BUD 10/26/2026; AP-202628, BUD 10/27/2026; AP-202629, BUD 10/28/2026; AP-202630, BUD 10/31/2026; AP-202631, BUD 11/01/2026; AP-202632, BUD 11/03/2026; AP-202633, BUD 11/07/2026; AP-202634, BUD 11/08/2026; AP-202635, BUD 11/16/2026; AP-202636, BUD 11/17/2026; AP-202637,BUD 11/18/2026; AP-202638, BUD 11/19/2026; AP-202639, BUD 11/20/2026; AP-202640, BUD 11/21/2026;AP-202641, BUD 11/22/2026; AP-202642, BUD 11/24/2026; AP-202643, BUD 11/25/2026; AP-202644, BUD 11/26/2026
Quantity (FDA field): 22 vials
FDA description: Tirzepatide Injection, 18mg/mL, 4 mL Sterile Multi-Dose Vial, Rx only, Apothecary Pharma, LLC, 1913 Evans Road, Cary, NC 27513, NDC 85091-001-18.
Recall number: D-0036-2027
FDA Enforcement Report, event 99952 · Distribution: Nationwide within the United States
Carolina Infusion, LLC
Tirzepatide, semaglutide (some with cyanocobalamin), sermorelin · Ridgeland, SC · 503A pharmacy
- Recall started
- September 10, 2026
- FDA classified
- October 8, 2026
- Public announcement
- None found
- Status in FDA record
- Ongoing
FDA reason: “Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product.”
The same FDA event also recalls seven non-peptide Tri-Mix and Quad-Mix products (16 products in total). See the full FDA record.
9 recalled products: lots and dates
Tirzepatide 26 mg/mL, syringes
Lots (FDA wording): Lots: 09012026@3, BUD: 10/16/2026; 08032026@16, BUD: 9/17/2026; 08052026@8, BUD: 9/19/2026; 08072026@13, BUD: 9/21/2026.
Quantity (FDA field): 5.6 mLs - in patient specific syringe doses
FDA description: TIRZEPATIDE 26 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescription, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936;
Recall number: D-0017-2027
Semaglutide 3 mg/mL, syringes
Lots (FDA wording): Lot: 08262026@6, BUD:10/10/2026.
Quantity (FDA field): 8 x 0.1 ml syringes
FDA description: SEMAGLUTIDE 3 MG/ML INJECTABLE, 8 x 0.1 mL syringes, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936
Recall number: D-0018-2027
Semaglutide/cyanocobalamin 3/2 mg/mL, syringes
Lots (FDA wording): Lot: 07282026@3, BUD: 9/11/2026; 08252026@9, BUD: 10/9/2026; 08042026@12, BUD: 9/18/2026; 08072026@15, BUD: 9/21/2026.
Quantity (FDA field): 57.0 mls - in patient specific syringe doses
FDA description: SEMAGLUTIDE/CYANOCOBALAMIN 3/2 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescription, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936
Recall number: D-0019-2027
Sermorelin acetate 1 mg/mL, syringes
Lots (FDA wording): Lot: 07292026@12, BUD 09/12/2026; 07302026@7, BUD 09/13/2026.
Quantity (FDA field): 15 mls - in patient specific syringe doses
FDA description: SERMORELIN ACETATE 1 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescription, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland
Recall number: D-0020-2027
Semaglutide/cyanocobalamin 9/2 mg/mL, syringes
Lots (FDA wording): Lot: 07242026@1, BUD: 9/7/2026; 08032026@20, BUD: 9/17/2026; 08312026@16, BUD: 10/15/2026; 08242026@28, BUD: 10/8/2026; 08072026@16, BUD: 9/21/2026.
Quantity (FDA field): 82.9 mls - in patient specific syringe dose
FDA description: SEMAGLUTIDE/CYANOCOBALAMIN 9/2 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescription, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936
Recall number: D-0026-2027
Tirzepatide/cyanocobalamin 26/2 mg/mL, syringes
Lots (FDA wording): Lot:07212026@18, BUD: 9/4/2026; 07222026@14, BUD: 9/5/2026; 07292026@8, BUD: 9/12/2026; 08052026@14, BUD: 9/19/2026; 08142026@1, BUD: 9/28/2026; 08192026@10, BUD: 10/3/2026; 08242026@25, BUD: 10/8/2026; 08282026@2, BUD: 10/12/2026; 08292026@1, BUD:10/13/2026;
Quantity (FDA field): 297 mL - in patient specific syringe dose
FDA description: TIRZEPATIDE/CYANOCOBALAMIN 26/2 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescription, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936
Recall number: D-0027-2027
Tirzepatide/cyanocobalamin 64/2 mg/mL, syringes
Lots (FDA wording): Lot:07252026@3, BUD: 9/8/2026; 08112026@5, BUD: 9/25/2026; 08212026@21, BUD: 10/5/2026; 08282026@3, BUD: 10/12/2026.
Quantity (FDA field): 29.6 mls - in patient specific syringe dose
FDA description: TIRZEPATIDE/CYANOCOBALAMIN 64/2 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescription, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936
Recall number: D-0028-2027
Tirzepatide/cyanocobalamin 76/2 mg/mL, syringes
Lots (FDA wording): Lot:08032026@23, BUD: 9/17/2026; 08172026@19, BUD: 10/1/2026; 08262026@13, BUD: 10/10/2026.
Quantity (FDA field): 24.8 mLs -in patient specific syringe dose
FDA description: TIRZEPATIDE/CYANOCOBALAMIN 76/2 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescription, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936
Recall number: D-0029-2027
Tirzepatide/cyanocobalamin 85/2 mg/mL, syringes
Lots (FDA wording): Lot:07212026@9, BUD: 9/4/2026; 07252026@2, BUD: 9/8/2026; 08122026@14, BUD: 9/26/2026; 08272026@8, BUD: 10/11/2026; 08312026@18, BUD: 10/15/2026.
Quantity (FDA field): 30.4 mLs - in patient specific syringe dose
FDA description: TIRZEPATIDE/CYANOCOBALAMIN 85/2 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescription, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936;
Recall number: D-0030-2027
FDA Enforcement Report, event 99867 · Distribution: Nationwide within the U.S
Optimal Balance Pharmacy
Glutathione · Houston, TX
- Recall started
- August 5, 2026
- FDA classified
- September 16, 2026
- Public announcement
- August 20, 2026
- Status in FDA record
- Ongoing
FDA reason: “Microbial Contamination of Sterile Products - out of specifications results were obtained for bacterial endotoxin.”
The company announcement (dated August 19, posted by FDA August 20) lists 14 states; FDA's enforcement record says USA Nationwide.
1 recalled product: lots and dates
Glutathione 200 mg/mL, 30 mL vial
Lots (FDA wording): Lot#: LG342009076, Beyond Use Date: 10/4/26
Quantity (FDA field): 53 vials
FDA description: Glutathione 200 mg/mL, 30 mL sterile multidose vial, Each vial contains: Glutathione, Ascorbic Acid, Benzyl Alcohol & sterile water for injection, For IM or IV Injection Use Only, RX only, Optimal Balance Pharmacy, 2204 Cypress Creek Pkwy Suite F, Houston, TX 77090
Recall number: D-0851-2026
FDA Enforcement Report, event 99662 · Distribution: USA Nationwide.
Apollo Care, LLC
Semaglutide (some with glycine) · Columbia, MO · 503B outsourcing facility
- Recall started
- July 29, 2026
- FDA classified
- August 7, 2026
- Public announcement
- None found
- Status in FDA record
- Ongoing
FDA reason: “Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material”
11 recalled products: lots and dates
Semaglutide 12.5 mg (2.5 mg/mL), 5 mL vial
Lots (FDA wording): Lot: AC-017108, Exp. 11/17/2026; AC-017110, Exp. 11/20/2026; AC-017112, Exp. 11/21/2026; AC-017142, AC-017144, Exp. 12/10/2026; AC-017166, AC-017167, AC-017177, AC-017213, AC-017224, AC-017225, Exp. 12/31/2026
Quantity (FDA field): 56,918 vials.
FDA description: SEMAGLUTIDE 12.5MG (2.5MG/mL), 5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202. NDC 71170-495-05
Recall number: D-0747-2026
Semaglutide 2.25 mg (0.9 mg/mL), 2.5 mL vial
Lots (FDA wording): Lot: AC-017114, Exp. 11/24/2026; AC-017164, AC-017204, AC-017205, Exp. 12/31/2026.
Quantity (FDA field): 23,029 vials.
FDA description: SEMAGLUTIDE 2.25MG (0.9 mg/mL), 2.5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202 NDC 71170-811-02
Recall number: D-0748-2026
Semaglutide 6.75 mg (4.5 mg/mL), 1.5 mL vial
Lots (FDA wording): Lot: C-017115, Exp. 11/25/2026; AC-017163, Exp. 12/31/2026; AC-017169, AC-017170, AC-017171, Exp. 12/31/2026; AC-017230, AC-017231, Exp. 5/5/2027.
Quantity (FDA field): 37,546 vials.
FDA description: SEMAGLUTIDE 6.75mg (4.5 mg/mL), 1.5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202 NDC 71170-821-01
Recall number: D-0749-2026
Semaglutide 4.5 mg (0.9 mg/mL), 5 mL vial
Lots (FDA wording): Lot: AC-017124, Exp. 8/30/2026; AC-017136, Exp. 12/31/2026.
Quantity (FDA field): 9,762 vials.
FDA description: SEMAGLUTIDE 4.5mg (0.9 mg/mL), 5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202. NDC 71170-812-03
Recall number: D-0750-2026
Semaglutide 9 mg (4.5 mg/mL), 2 mL vial
Lots (FDA wording): Lot: AC-017125, Exp. 8/30/2026; AC-017138, AC-017147, AC-017214, AC-017226, AC-017228, Exp. 12/31/2026.
Quantity (FDA field): 24,608 vials.
FDA description: SEMAGLUTIDE 9mg (4.5 mg/mL), 2 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202. NDC 71170-822-02
Recall number: D-0751-2026
Semaglutide 0.9 mg (0.9 mg/mL), 1 mL vial
Lots (FDA wording): Lot: AC-017131, Exp. 8/30/2026.
Quantity (FDA field): 4,748 vials.
FDA description: SEMAGLUTIDE 0.9mg (0.9 mg/mL), 1 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202. NDC 71170-810-01
Recall number: D-0752-2026
Semaglutide 2.5 mg / glycine 12.5 mg, 2.5 mL vial
Lots (FDA wording): Lot: AC-017271, Exp. 12/12/2026.
Quantity (FDA field): 250 vials.
FDA description: SEMAGLUTIDE 2.5mg (1mg/mL), Glycine 12.5 mg (5mg/mL), 2.5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801Mojave Ct, Ste 102, Columbia, MO 65202. NDC 71170-711-02
Recall number: D-0753-2026
Semaglutide 5 mg / glycine 25 mg, 5 mL vial
Lots (FDA wording): Lot: AC-017272, Exp. 12/12/2026.
Quantity (FDA field): 250 vials.
FDA description: SEMAGLUTIDE 5mg (1mg/mL), Glycine 25 mg (5mg/mL), 5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202.NDC 71170-712-03
Recall number: D-0754-2026
Semaglutide 7.5 mg / glycine 7.5 mg, 1.5 mL vial
Lots (FDA wording): Lot: AC-017273, Exp. 12/12/2026.
Quantity (FDA field): 250 vials.
FDA description: SEMAGLUTIDE 7.5mg (5mg/mL), Glycine 7.5 mg (5mg/mL), 1.5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202. NDC 71170-721-01
Recall number: D-0755-2026
Semaglutide 10 mg / glycine 10 mg, 2 mL vial
Lots (FDA wording): Lot: AC-017274, Exp. 12/12/2026.
Quantity (FDA field): 500 vials.
FDA description: SEMAGLUTIDE 10mg (5mg/mL), Glycine 10 mg (5mg/mL), 2 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202. NDC 71170-722-02
Recall number: D-0756-2026
Semaglutide 20 mg / glycine 20 mg, 4 mL vial
Lots (FDA wording): Lot: AC-017275, Exp. 12/13/2026; AC-017282, AC-017285, Exp. 12/27/2026.
Quantity (FDA field): 4,250 vials.
FDA description: SEMAGLUTIDE 20mg (5mg/mL), Glycine 20 mg (5mg/mL), 4 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202. NDC 71170-724-04.
Recall number: D-0757-2026
FDA Enforcement Report, event 99505 · Distribution: Nationwide within the U.S
Centric Compounding LLC
Glutathione; glutathione-containing blends · Tomball, TX (labels: Houston, TX)
- Recall started
- July 27, 2026
- FDA classified
- October 16, 2026
- Public announcement
- September 13, 2026
- Status in FDA record
- Ongoing
FDA reason: “Microbial Contamination of Sterile Products - out of specifications results were obtained for bacterial endotoxin.”
FDA's enforcement record lists the firm in Tomball, TX; product labels and the company announcement say Houston, TX.
3 recalled products: lots and dates
Glutathione 200 mg/mL, 30 mL vial
Lots (FDA wording): Lot #: 062326:B, Beyond Use Date 8/7/26; 070826:A, Beyond Use Date: 8/22/26; 072726:D, Beyond Use Date: 9/25/26
Quantity (FDA field): 45 vials
FDA description: Glutathione 200 mg/mL, 30 mL multi-dose vial, Rx only, Centric Compounding, 7447 Harwin Dr. Suite 111, Houston, TX 77036
Recall number: D-0046-2027
Myers Cocktail (contains glutathione), 30 mL vial
Lots (FDA wording): Lot #: 070226:D, Beyond Use Date: 8/16/26; 072126:A, Beyond Use Date: 9/4/26
Quantity (FDA field): 9 vials
FDA description: Multidose Myers Cocktail (Ascorbic Acid 500 mg/10 mL, Calcium Gluconate 10 mg/mL. Calcium Panthothenate 2 mg/10 mL, Glutathione-L 200 mg/10mL, Magnesium Chloride 800 mg/10 mL, Methylcobalamin 1 mg/10 mL, B-Complex 1 ml/10 mL, Zinc Sulfate 2.5 mg/10 mL) IV injection, 3 Myers Cocktails (1 Myers/10 mL), 30 mL vial, Rx only, Centric Compounding, 7447 Harwin Dr. Suite 111, Houston, TX 77036
Recall number: D-0047-2027
Tri-Immune Boost (contains glutathione), 30 mL vial
Lots (FDA wording): Lot #: 071626:B, Beyond Use Date: 8/30/26
Quantity (FDA field): 3 vials
FDA description: Tri-Immune Boost (Glutathione: 200 mg, Ascorbic Acid: 200 mg, Zinc: 2.5 mg), 30 mL vial, Rx only, Centric Compounding, 7447 Harwin Dr. Suite 111, Houston, TX 77036
Recall number: D-0048-2027
FDA Enforcement Report, event 99860 · Distribution: USA Nationwide.
Victory Medical Center Pharmacy
Glutathione · Austin, TX · 503A pharmacy
- Recall started
- July 1, 2026
- FDA classified
- August 19, 2026
- Public announcement
- August 5, 2026
- Status in FDA record
- Ongoing
FDA reason: “Microbial Contamination of Sterile Products - out of specifications results were obtained for bacterial endotoxin.”
1 recalled product: lots and dates
Glutathione 200 mg/mL, 30 mL vial
Lots (FDA wording): Lot # 1984345, 1980571, 1981940, Use Before Date: 08/27/2026.
Quantity (FDA field): 91
FDA description: Glutathione (MDV), 200 mg/mL, 30 mL vial, each mL contains Glutathione 200 mg, Ascorbic Acid 20 mg, Benzyl Alcohol 1.5%, Na Hydroxide (Ph Adjust) in sterile water for injection, VMC.
Recall number: D-0772-2026
FDA Enforcement Report, event 99509 · Distribution: USA Nationwide
What the recall classes mean
The FDA assigns each recall a class based on the health risk:
- Class I: a reasonable probability that using the product will cause serious adverse health consequences or death.
- Class II: using the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.
- Class III: using the product is not likely to cause adverse health consequences.
A recall's start date, its FDA classification date, and any public announcement are often weeks apart. We list each date separately and leave a date blank when the FDA hasn't published it.
What's included, and what isn't
This tracker covers compounded peptide and peptide-containing products: semaglutide, tirzepatide, sermorelin, and glutathione, including blends. When an FDA recall event also includes non-peptide products, we note it and link to the full record.
It doesn't cover recalls of FDA-approved, factory-made peptide medicines, such as insulin, glucagon, or exenatide. Those appear in the FDA's Enforcement Report alongside all other drug recalls.
For where each peptide stands on FDA approval and compounding, see our FDA status tracker.
Patterns worth knowing
- Glutathione and endotoxin. All four Class I recalls involve compounded glutathione. Three cite bacterial endotoxin test results; Greenwich Rx's record cites microbial contamination of sterile products.
- The largest recall got the least attention. Apollo Care's July recall of compounded semaglutide covers 11 products and more than 160,000 vials, by the FDA's quantity fields, over particulate matter the FDA record identifies as nylon/polyamide and silk/proteinaceous-type material.
- Not every recall gets a press release. For four of the eight recalls here, we found no FDA-posted public announcement. They appear in the Enforcement Report.
How we keep this current
We check the FDA Enforcement Report each week and add new peptide recalls with their FDA links. The FDA's databases can lag, and a recall can appear before it's classified, so a product missing from this list hasn't necessarily been cleared. Our guide to checking a recall explains how to search the FDA's records yourself.
This tracker is for general information and isn't medical advice. If you have a recalled product, follow the recall notice and talk to your prescriber or pharmacist.
What this article is based on
Checked October 27, 2026. Primary FDA documents are listed first where available.
About this content: The Peptide Verdict is an independent educational publication. Articles are researched and written with AI assistance, edited by our editorial team, and checked against the primary sources listed on each page. They are not reviewed by a medical professional and are not medical, legal, or pharmacy advice. Peptide regulations change quickly; always check the dates shown and confirm current rules. Talk to a licensed clinician before using any peptide or medication.